AC Immune
Optionality in neurodegeneration, but quality screens say to wait
AC Immune is a clinical‑stage Swiss biotech focused on precision therapeutics and diagnostics in neurodegeneration, with two proprietary platforms (SupraAntigen and Morphomer) and multiple partnered programs.
The company has struck notable non‑dilutive deals, including Takeda’s option and license for the anti‑amyloid vaccine ACI‑24.060 with a 100 million dollar upfront and up to about 2.1 billion dollars in milestones, and an April 2026 amendment with Eli Lilly on Tau small molecules that added a 10 million Swiss franc upfront.
Several near‑term data readouts could be pivotal: 12‑month ABATE Phase 2 interim data in Alzheimer’s disease are guided for the second quarter of 2026, final Part 1 Phase 2 data for the Parkinson’s vaccine ACI‑7104 in the second half of 2026, and new first‑in‑human images from the TDP‑43 PET tracer program were presented in March and expanded in May 2026. These scientifically interesting assets, if de‑risked, could unlock additional partner milestones and strategic optionality.
From a quality‑value lens, however, AC Immune does not yet meet our preference for predictable, high‑margin, cash‑generative businesses. TTM free cash flow is negative, the revenue base is small and milestone‑dependent, and key efficacy readouts remain ahead.
The company reports cash and short‑term financial assets of 74.8 million Swiss francs at March 31, 2026, with runway into the fourth quarter of 2027 and no financial debt, but the 2025 operating cash outflow was 69.3 million Swiss francs.
Given 10‑year US Treasuries around the mid‑4 percents in May 2026, the opportunity cost for capital is meaningful until AC Immune converts its pipeline into durable cash flows. Our stance is to watch for ABATE AD data and Parkinson’s Part 1 readout and reassess after any Takeda option decision.
Does AC Immune have a strong competitive moat?
Intangible assets: AC Immune’s differentiated platforms (SupraAntigen for active immunotherapies and Morphomer for small molecules) and first‑in‑human PET imaging capability for TDP‑43 are defensible through IP and know‑how.
The TDP‑43 tracer program is potentially first‑in‑class and could create a diagnostics wedge that supports precision prevention studies. However, these remain pre‑commercial and efficacy risk is high.
Switching costs: For partners, switching costs can be meaningful once programs progress, evidenced by ongoing Takeda and Lilly collaborations; for patients/prescribers, switching costs would depend on eventual label and real‑world outcomes. Network effects: Limited.
Diagnostics like PET can gain embeddedness within trial networks but do not exhibit classic network effects. Cost advantage: Active immunization could prove more convenient and potentially less costly than chronic infusions, but this is unproven without late‑stage outcomes and pricing.
Competing mAbs are expensive and complex to administer, but they are already approved and set the clinical efficacy bar. Efficient scale: If one or more programs succeed, the combination of platform breadth and partnerships could create an efficient capital model, yet today the company is sub‑scale with negative cash flows.
Overall, the moat is nascent and contingent on clinical success rather than established.
Does AC Immune have pricing power in its industry?
There is no proven pricing power yet because no product is on the market. If successful, an Alzheimer’s or Parkinson’s active vaccine could command premium pricing versus standard vaccines but likely below the list prices of monoclonal antibodies such as donanemab and lecanemab, which run in the tens of thousands of dollars annually.
Any realized pricing power will hinge on demonstrable disease‑modifying efficacy, ARIA/safety profile advantages, and payer acceptance relative to anti‑amyloid antibodies that are already covered by Medicare. At this stage, latent pricing power exists in theory but cannot be relied upon.
How predictable is AC Immune's business?
Revenue is minimal and milestone‑driven, while free cash flow is negative and dependent on R&D cadence and partner inflows.
Key value drivers are binary: ABATE Phase 2 12‑month interim AD data in Q2 2026, Parkinson’s Part 1 final data H2 2026, and the trajectory of Janssen’s ReTain Phase 2b where enrollment is paused pending a protocol amendment to yield earlier biological insights. These uncertainties materially limit forecasting reliability.
Is AC Immune financially strong?
AC Immune reported 74.8 million Swiss francs in cash and short‑term financial assets at March 31, 2026 and indicates runway into the fourth quarter of 2027, aided by partnerships. The company reported 69.3 million Swiss francs of operating cash outflow in 2025, reflecting the capital intensity of clinical development.
There is no financial debt disclosed, but sustainability depends on milestone timing and/or future capital raises. Overall liquidity is adequate for near‑term catalysts, but not yet self‑funding.
How effective is AC Immune's capital allocation strategy?
Management has leaned on high‑quality partners to fund programs, limiting dilution: 100 million dollar upfront from Takeda in 2024 with up to about 2.1 billion dollars in milestones, and a 10 million Swiss franc upfront in April 2026 from Lilly for Tau small molecules.
Deferred revenue of roughly 86 million Swiss francs at year‑end 2025 reflects contracted future work. The company maintains an ATM facility but had no ATM share sales in 2025; treasury shares remain available. Capex is low; spend is overwhelmingly R&D.
While milestone reliance is a risk, the partnership‑first approach is rational for a platform biotech.
Does AC Immune have high-quality management?
Founder‑CEO Dr. Andrea Pfeifer has historically secured multiple large‑pharma deals and owns meaningful equity; however, she announced plans to retire at the upcoming 2026 AGM, with the board chair to serve as interim CEO during the search. Governance includes experienced industry figures, though the transition adds uncertainty before pivotal data.
Insider and major holders include BVF and dievini Hopp BioTech. On balance, the track record on partnering is strong, but leadership transition ahead of key readouts tempers our score.
Is AC Immune a quality company?
AC Immune is a weak quality company with a quality score of 44/100
- Multiple partnered shots on goal: Takeda option on ACI‑24.060 (100 million dollar upfront; up to about 2.1 billion dollars in milestones) and an April 2026 Lilly amendment on Morphomer Tau (10 million Swiss franc upfront) reduce financing risk.
- Near‑term catalysts: ABATE AD cohorts AD1–AD3 12‑month interim results expected in Q2 2026; ACI‑7104 Phase 2 Part 1 final data expected H2 2026; new human imaging data for first‑in‑class TDP‑43 PET presented in 2026.
- Financial position: 74.8 million Swiss francs in cash and short‑term financial assets as of March 31, 2026; runway into Q4 2027; no financial debt disclosed. 2025 operating cash outflow was 69.3 million Swiss francs.
- Clinical signals: Parkinson’s vaccine ACI‑7104 interim Phase 2 data showed 100% responder immunogenicity and biomarker stabilization trends; anti‑pTau vaccine ACI‑35.030 advanced into Janssen’s ReTain Phase 2b but enrollment is currently paused pending protocol amendment to enable earlier biological readouts.
- Competitive context: Anti‑amyloid antibodies lecanemab and donanemab are already approved and costly to administer, which could support vaccine convenience but also raises the efficacy bar and regulatory scrutiny; earlier Genentech/AC Immune anti‑Tau antibody semorinemab failed to show broad clinical benefit in Phase 2.
What is the fair value of AC Immune stock?
Is AC Immune a good investment at $2.70?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.